SRX Global to Acquire CERo Therapeutics in SPV Deal

SRX Global Inc. (NYSE American: SRXH) said on 7 October 2026 that it entered a definitive purchase agreement to acquire CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO), making it a wholly owned SRX subsidiary. The buyer is CERO 1236, a wholly owned special purpose vehicle. SRX said capital will be raised directly into that SPV rather than at the parent, so existing SRX Global shareholders are not diluted. CERo's lead candidate, CER-1236, has treated six patients in the Phase 1 CERTAIN-T trial.

Context — why the SPV structure matters now

The deal's defining feature is where the money sits. SRX Global describes itself as an AI-enabled platform that invests in high-conviction operating companies. Rather than issuing parent-level stock to fund an oncology program, it routes the raise through a subsidiary it owns outright. The company said the SPV will raise capital directly and that this does not dilute existing SRX Global shareholders.

That framing answers the question a biotech acquisition usually raises first: who pays for the next trial cohort. SRX said the combination of CERo and the CERO 1236 SPV is expected to benefit from enhanced access to capital. It also said the transaction combines SRX's public company infrastructure with CERo's oncology platform.

CERo's own position explains the urgency. CERo Holdings trades on the OTCQB tier rather than a national exchange, and its operating subsidiary is the entity being sold. SRX said the pending transaction is expected to accelerate advancement of CERo's clinical programs. The report does not disclose the purchase price, the consideration mix, or the amount of capital the SPV intends to raise.

Leadership continuity is written into the structure. Andrew Kucharchuk, currently CERo's chief financial officer, is expected to serve as President and primary executive of CERo Therapeutics after closing. Chris Ehrlich, CERo's chief executive, and current CERo director Brian Atwood are each expected to join the CERo Therapeutics board and serve as Special Advisors to the President.

SRX chief executive Kent Cunningham tied the deal to a stated pattern, saying it reflects a strategy of investing in high-conviction operating companies with meaningful long-term value creation potential. Ehrlich said the transaction provides a stronger platform from which to execute CERo's clinical development strategy.

Data — what the numbers show

The clinical figures are the hard numbers in the report. CERo has reported treating six patients in the ongoing Phase 1 CERTAIN-T trial. In the most recent cohort of three patients, CER-1236 was given at an increased dose level, and CERo reported no dose-limiting toxicities during the DLT assessment period.

The company also said it has observed expansion of infused CER-1236 cells after administration and continues to evaluate the candidate's pharmacokinetic and pharmacodynamic profile as the study advances through dose escalation. CERo states plainly that these results are preliminary and not sufficient to establish safety or efficacy.

Metric	Reported position
Patients treated in CERTAIN-T	6
Most recent cohort size	3
Dose-limiting toxicities in that cohort	0
Next planned dose	1 billion cells per patient

The escalation path is the forward number. CERo has initiated the third planned cohort, which is expected to evaluate a planned one billion cells per patient protocol, and is screening patients for enrollment. That cohort is also expected to include patients with myelodysplastic syndromes and myelofibrosis.

The report gives no valuation, no share count, no cash figure, and no timeline for closing. SRX Global's own market capitalization and share price are not stated in the report.

Analysis — what it means for markets and sectors

The deal sits in the engineered T cell corner of oncology, where CERo positions its approach as integrating innate and adaptive immunity into a single construct. CERo calls these cells Chimeric Engulfment Receptor T cells, or CER-T. The company frames the mechanism as engaging multiple immune mechanisms against cancer.

The disease list is where the commercial logic shows. CERTAIN-T began in acute myeloid leukemia, including relapsed or refractory AML, measurable residual disease AML, and newly diagnosed TP53-mutated AML. It has since expanded to transfusion-dependent and high-risk myelodysplastic syndromes and post-JAK inhibitor myelofibrosis.

Myelofibrosis matters because it is a JAK-inhibitor-adjacent setting, putting CER-1236 in the same patient pool that hematology franchises already screen. The third cohort folds MDS and MF into the same dose-escalation protocol, which CERo describes as a strategy to evaluate the candidate in additional myeloid disease settings.

The counter-argument is the one CERo states itself. Six patients, no DLTs in a three-patient cohort, and observed cell expansion do not establish safety or efficacy. Dose escalation trials routinely produce clean early cohorts before later toxicity or efficacy failures, and the report offers no response-rate data from any cohort.

The structural risk is the go-shop. SRX's own forward-looking language flags the possibility that the go-shop process produces a superior proposal and the purchase agreement is terminated, including payment of termination fees. It also flags failure to satisfy closing conditions, including those related to CERo Holdings' preferred stock, and changes in the value or liquidity of SRX common stock issued as consideration.

That last point confirms stock is part of the consideration, even though the report does not give the split. SRXH holders carry exposure to an oncology program whose funding runs through a subsidiary, while CERO holders on the OTCQB are being folded into a NYSE American-listed parent. Positioning runs through that listing migration as much as through the clinical data.

Outlook — what to watch next

The nearest catalyst is enrollment. CERo said it is currently screening patients for the third CERTAIN-T cohort, the one expected to test the one billion cells per patient protocol and to add MDS and MF patients. Any disclosure on that cohort's dosing or DLT window is the next clinical read.

Second is the go-shop. SRX's forward-looking statements contemplate a superior proposal emerging and the agreement terminating with termination fees paid. The report does not give the go-shop window length or the fee amount, so the trigger to watch is any announcement that the agreement has been terminated or amended.

Third is the SPV raise itself. SRX said capital will be raised directly into CERO 1236 without diluting existing SRX Global shareholders, but gave no size, timing, or structure. Closing also depends on conditions tied to CERo Holdings' preferred stock, which the report identifies but does not quantify.

Frequently Asked Questions

What does the SRX Global and CERo Therapeutics deal mean for retail investors?

For SRX Global holders, the stated benefit is that the capital raise happens inside CERO 1236, a wholly owned SPV, rather than at the parent, so the company says existing shareholders are not diluted. For CERo Holdings holders on the OTCQB, the operating subsidiary moves under a NYSE American-listed parent. The report does not disclose the purchase price or the consideration split.

What is CER-1236 and how far along is it?

CER-1236 is CERo's lead investigational product candidate, being evaluated in hematologic malignancies. CERo has reported treating six patients in the Phase 1 CERTAIN-T trial, with no dose-limiting toxicities in the most recent three-patient cohort at an increased dose. CERo has initiated a third cohort expected to test one billion cells per patient and is screening patients.

Why is SRX Global using a special purpose vehicle for this acquisition?

SRX said capital will be raised directly into CERO 1236, a wholly owned subsidiary, rather than at the parent level, and that this avoids dilution for existing SRX Global shareholders. The company also said the combination of CERo and the SPV is expected to benefit from enhanced access to capital to advance CER-1236 and broader research and development.

Bottom Line

SRX Global is buying CERo Therapeutics through an SPV that carries the funding, leaving SRX holders undiluted but dependent on a six-patient Phase 1 readout.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.